Kazuo Kasahara

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

Hideharu Kimura, Kazuo Kasahara, Makoto Kawaishi et al. · Clinical Cancer Research · 2006 · 324 citations · Full text

Medicine, Oncology, Pharmacology +16

Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study

Fumiko Taguchi, Benjamin Solomon, Vanesa Gregorc et al. · JNCI Journal of the National Cancer Institute · 2007 · 315 citations · Full text

Medicine, Oncology, Pharmacology +16

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)

Hideharu Kimura, Mika Suminoe, Kazuo Kasahara et al. · British Journal of Cancer · 2007 · 204 citations · Full text

Medicine, Molecular Genetics, Oncology +16